100 sponsored registrations will be offered to civil society members, individuals involved in efforts to address lung health, and survivors of TB. Deadline for applications: 18 July 2024

The TB Vaccine Advocacy Roadmap (TB Vax ARM) will host a webinar on 16 July 2024 on the latest updates in the TB vaccine space.

New Delhi: In a big victory for TB activism and children suffering from TB in India, the country’s patent office rejected Johnson & Johnson’s (J&J) patent application for the paediatric formulation of Bedaquiline on Friday, July 5.

South Africa's anti-trust regulator announced on July 5 that drugmaker Johnson & Johnson (J&J) and its subsidiary, Janssen Pharmaceutical, have agreed to withdraw a secondary patent on the tuberculosis (TB) drug bedaquiline.

The resurgence of detected TB infections after the pandemic has revealed persistent challenges in Southeast Asia, where socioeconomic factors exacerbate the disease's prevalence. Innovative strategies, such as AI-assisted detection and international cooperation, are critical to eliminating the scourge.

The World Health Organization (WHO) provided updates on several important events hosted by the organization and its partners in June 2024 in Dhaka, Bangladesh: first Global Forum on Advancing Multisectoral and Multistakeholder Engagement and Accountability to End TB (23-24 June); #Youth2EndTB Townhall (23 June); annual meeting of the Stop TB Working Group on Public-Private Mix (PPM) for TB prevention and care (25-26 June); consultation on enhanced TB-PPM data dashboards with seven PPM priority countries (27 June). The WHO policy brief: "Public-Private Mix Data Dashboards for Enhanced Action and Accountability to End TB" was launched and disseminated at the consultation.

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

Borstel researchers are the first to develop a biomarker to predict the occurrence of neuropathic adverse events during therapy for multidrug-resistant tuberculosis. The results have now been published in the journal Pathogens & Immunity.

Deadline for applications: 12 July 2024

RESIST-TB released its July 2024 newsletter with the latest updates and research publications on drug-resistant TB.